[go: up one dir, main page]

CY2151B1 - Fusionproteins with parts of immunoglobulins theirproduction and use - Google Patents

Fusionproteins with parts of immunoglobulins theirproduction and use

Info

Publication number
CY2151B1
CY2151B1 CY9900007A CY9900007A CY2151B1 CY 2151 B1 CY2151 B1 CY 2151B1 CY 9900007 A CY9900007 A CY 9900007A CY 9900007 A CY9900007 A CY 9900007A CY 2151 B1 CY2151 B1 CY 2151B1
Authority
CY
Cyprus
Prior art keywords
theirproduction
fusionproteins
immunoglobulins
parts
protein
Prior art date
Application number
CY9900007A
Inventor
Leander Dr Lauffer
Patricia Dr Oquendo
Gerd Dr Zettlmeissl
Brian Dr Seed
Original Assignee
Gen Hospital Corp
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Hoechst Ag filed Critical Gen Hospital Corp
Publication of CY2151B1 publication Critical patent/CY2151B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A soluble fusion protein (I) comprising a human protein (II), or part of it, that is not of the immunoglobulin (Ig) family and different parts (III) of Ig molecules of any subclass, is new. An independent claim is also included for a method for preparing (I) by introducing a DNA that encodes it into a mammalian cell expression system, expressing (I), and purification by affinity chromatography through the Ig component. ACTIVITY : Hemostatic; Immunosuppressive; Antiallergic; Antianemic; Anticoagulant; Thrombolytic. No details of tests for these activities are given. MECHANISM OF ACTION : Protein substitution or inhibition.
CY9900007A 1990-06-28 1999-02-12 Fusionproteins with parts of immunoglobulins theirproduction and use CY2151B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4020607 1990-06-28

Publications (1)

Publication Number Publication Date
CY2151B1 true CY2151B1 (en) 2002-08-23

Family

ID=6409260

Family Applications (2)

Application Number Title Priority Date Filing Date
CY9900007A CY2151B1 (en) 1990-06-28 1999-02-12 Fusionproteins with parts of immunoglobulins theirproduction and use
CY2000009C CY2000009I1 (en) 1990-06-28 2014-06-18 FUSION PROTEINS WITH IMMUNOSPHEREIN PARTS, THEIR PREPARATION AND USE

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2000009C CY2000009I1 (en) 1990-06-28 2014-06-18 FUSION PROTEINS WITH IMMUNOSPHEREIN PARTS, THEIR PREPARATION AND USE

Country Status (17)

Country Link
EP (3) EP0835939B8 (en)
JP (2) JPH05247094A (en)
KR (3) KR100249572B1 (en)
AT (2) ATE309376T1 (en)
AU (1) AU655421B2 (en)
CA (1) CA2045869C (en)
CY (2) CY2151B1 (en)
DE (3) DE59109032D1 (en)
DK (2) DK0835939T3 (en)
ES (2) ES2120949T4 (en)
GR (1) GR3027567T3 (en)
HK (2) HK1010216A1 (en)
IE (1) IE912256A1 (en)
LU (1) LU90592I2 (en)
NL (1) NL300009I2 (en)
PT (1) PT98113B (en)
UY (1) UY25897A1 (en)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
DE59010933D1 (en) * 1989-09-12 2003-05-08 Hoffmann La Roche TFN-binding proteins
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
DE4322330A1 (en) 1992-08-31 1994-03-03 Behringwerke Ag Use of the IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, parasitic and bacterial diseases as well as fungal infections
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
DE4228839A1 (en) * 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
CA2161971A1 (en) * 1993-04-30 1994-11-10 Randal W. Scott Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
DE4407386B4 (en) * 1994-03-05 2009-01-15 Dade Behring Marburg Gmbh Method for reactivation of purified membrane proteins by freezing
CA2165412A1 (en) * 1994-04-28 1995-10-29 Barry John Woodhams Calibrator for prothrombin time (pt) assays
BR9508469A (en) * 1994-07-29 1997-09-16 Smithkline Beecham Plc Soluble protein having il4 and / or il13 antagonist or partial compound antagonist activity
CA2205572A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO1996022024A1 (en) * 1995-01-17 1996-07-25 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
DE19538716A1 (en) * 1995-10-18 1997-04-24 Behringwerke Ag Method for quantification of activated coagulation factor VII (FVIIa)
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
DE19538715A1 (en) 1995-10-18 1997-04-30 Behringwerke Ag Process for cleaning factor VII and activated factor VII
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
NZ334035A (en) 1996-08-16 2000-09-29 Human Genome Sciences Inc Use of endokine alpha antagonists to diagnose and treat TNF-related disorders
WO1998008870A1 (en) 1996-08-30 1998-03-05 Human Genome Sciences, Inc. Interleukin-19
WO1998018921A1 (en) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. NEUTROKINE $g(a)
ATE406176T1 (en) 1996-12-06 2008-09-15 Amgen Inc IL-1 INHIBITOR IN COMBINATION THERAPY FOR THE TREATMENT OF IL-1-MEDIATED DISEASES
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
AU6238698A (en) 1997-01-14 1998-08-03 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
DK1012274T4 (en) 1997-01-28 2011-07-25 Human Genome Sciences Inc Death domain-containing receptor-4 (DR4: death receptor 4), a member of the TNF receptor superfamily and which binds to TRAIL (Apo-2L)
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
DE69841994D1 (en) 1997-05-30 2010-12-23 Human Genome Sciences Inc 32 Human secreted proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
WO1999002709A1 (en) * 1997-07-10 1999-01-21 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
JP2002017353A (en) * 1997-12-19 2002-01-22 Japan Tobacco Inc Method for determining denaturated ldl
JP4409763B2 (en) 1998-01-23 2010-02-03 イミュネックス・コーポレーション ACPL DNA and polypeptides
WO1999047538A1 (en) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
WO2000023594A1 (en) 1998-10-22 2000-04-27 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
EP1612263A1 (en) 1998-12-31 2006-01-04 The General Hospital Corporation PTH receptor and screening assay utilizing the same
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU766507B2 (en) * 1999-05-07 2003-10-16 Genentech Inc. Novel chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6362324B1 (en) * 1999-06-30 2002-03-26 Millennium Pharmaceuticals, Inc. 17867 a novel human aminopeptidase
US6369210B1 (en) * 1999-06-30 2002-04-09 Millennium Pharmaceuticals, Inc. 22012, human carboxypeptidase
WO2001023521A2 (en) 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
EP1418234A4 (en) 2000-03-02 2005-03-16 Abgenix Inc Human monoclonal antibodies against oxidized ldl receptor and medicinal use thereof
EP1712239A3 (en) 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
JP4932125B2 (en) 2000-08-25 2012-05-16 ビーエーエスエフ プラント サイエンス ゲーエムベーハー Plant polynucleotides encoding novel prenyl proteases
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
MXPA03010747A (en) 2001-05-25 2004-03-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors.
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
CA2454275C (en) 2001-07-23 2012-10-23 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
KR100453877B1 (en) * 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
JP5116971B2 (en) 2002-10-15 2013-01-09 インターセル アーゲー Nucleic acid encoding an adhesion factor for group B streptococci, an adhesion factor for group B streptococci, and uses thereof
JP2006518997A (en) 2003-01-21 2006-08-24 ブリストル−マイヤーズ　スクイブ　カンパニー Novel acyl coenzyme A: polynucleotide encoding monoacylglycerol acyltransferase-3 (MGAT3) and uses thereof
EP2053125B1 (en) 2003-03-04 2014-04-30 Valneva Austria GmbH Streptococcus pyogenes antigens
AU2003220380A1 (en) 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
CA2522238A1 (en) 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2012203896B2 (en) * 2003-05-06 2014-09-25 Bioverativ Therapeutics Inc. Clotting Factor-Fc Chimeric Proteins to Treat Hemophilia
DK1624891T4 (en) 2003-05-06 2013-07-15 Biogen Idec Hemophilia Inc Chimeric coagulation factor Fc proteins for the treatment of haemophilia
CN101864431A (en) 2003-05-07 2010-10-20 英特塞尔股份公司 Streptococcus agalactiae antigens I and II
EP1629005A2 (en) 2003-05-30 2006-03-01 Intercell AG Enterococcus antigens
EP1653985A4 (en) 2003-07-17 2009-08-05 Gen Hospital Corp Conformationally constrained parathyroid hormone (pth) analogs
KR20050047030A (en) 2003-11-13 2005-05-19 한미약품 주식회사 Igg fc fragment for a drug carrier and method for the preparation thereof
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
DE602005022692D1 (en) 2004-04-22 2010-09-16 Talecris Biotherapeutics Inc RECOMBINANT MODIFIED PLASMINE
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US20070264277A1 (en) 2004-07-22 2007-11-15 Dirk Behrens Compositions and Methods of Use for Mgd-Csf in Disease Treatment
JP5334414B2 (en) 2004-09-06 2013-11-06 バイエル インテレクチュアル プロパティー ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel pyrazolopyrimidine
EP1819728B1 (en) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7 variants with reduced immunogenicity
CA2603863A1 (en) 2005-04-07 2006-10-19 The Cleveland Clinic Foundation Gammaretrovirus associated with cancer
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc Fragments Modified with Non-Peptide Polymers and Pharmaceutical Compositions Comprising the Same
RU2428430C2 (en) 2005-08-16 2011-09-10 Ханми Холдингс Ко., Лтд. METHOD OF MASS PRODUCTION OF Fc REGION OF IMMUNOGLOBULIN WITH REMOTE INITIAL METHIONINE RESIDUES
EP1931384A4 (en) 2005-09-09 2010-03-10 Univ Johns Hopkins HANDLING REGULATORY T CELLS AND DC FUNCTIONS BY TARGETING NEURITINE GENES USING ANTIBODY AGONISTS AND ANTAGONISTS
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
NZ568762A (en) 2005-11-07 2011-11-25 Scripps Research Inst Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
EP1785434A1 (en) 2005-11-11 2007-05-16 Ludwig-Maximilians-Universität München Targeting and tracing of antigens in living cells
WO2010093928A2 (en) 2009-02-12 2010-08-19 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
ES2683846T3 (en) 2006-01-20 2018-09-28 Cell Signaling Technology, Inc. ROS mutant and translocation kinase in human non-small cell lung carcinoma
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
CA2649535A1 (en) 2006-04-20 2007-11-01 Becton, Dickinson And Company Thermostable proteins and methods of making and using thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US8143374B2 (en) 2006-08-04 2012-03-27 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
KR100888022B1 (en) 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 Fusion protein between immunoglobulin Fc and human apolipoprotein (a) kringle fragment L8 8Fc
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2497779A1 (en) 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
AU2008265218A1 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
BRPI0814465B1 (en) 2007-07-26 2021-11-23 Novagen Holding Corporation FUSION PROTEIN, DIMER, METHOD FOR PRODUCING A FUSION PROTEIN, CELL LINEAGE, USES OF A FUSION PROTEIN AND A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION
EP2187902B1 (en) 2007-08-01 2013-04-17 The General Hospital Corporation Screening methods using g-protein coupled receptors and related compositions
EP2987859B1 (en) 2007-09-27 2018-08-08 Japan Tobacco Inc. Factor involved in latent infection with herpesvirus, and use thereof
CA2702686C (en) 2007-10-18 2023-04-04 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
ES2611102T3 (en) 2008-01-11 2017-05-04 Adheron Therapeutics, Inc. Antibodies with EC1 domain directed against cadherin-11 to treat inflammatory joint disorders
US10000568B2 (en) 2008-04-10 2018-06-19 Cell Signaling Technology, Inc. Compositions and methods for detecting EGFR in cancer
RU2497948C2 (en) 2008-06-04 2013-11-10 Тэйлкрис Байотерапьютикс, Инк. Composition, method and set for production of plasmin
EP2300501B1 (en) 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
HUE025670T2 (en) 2009-03-03 2016-04-28 Grifols Therapeutics Inc Methods for preparing plasminogen
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
EP2525808A2 (en) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
WO2013033680A1 (en) 2011-09-02 2013-03-07 Lifenet Health Bmp peptides & methods of use
JP5911848B2 (en) 2010-05-04 2016-04-27 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド Fibrosis detection and treatment
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
LT2593128T (en) 2010-07-15 2018-06-25 Adheron Therapeutics, Inc. Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP2855521A4 (en) 2012-05-24 2016-03-02 Mountgate Group Ltd COMPOSITIONS AND METHODS ASSOCIATED WITH THE PREVENTION AND TREATMENT OF RABIC INFECTION
EP2685260A1 (en) 2012-07-09 2014-01-15 Ludwig-Maximilians-Universität München Direct and quantitative detection of targets in living cells
KR101609840B1 (en) * 2012-07-12 2016-04-07 한국생명공학연구원 Adsorption column for antibody purification using Fc region binding peptide of antibody
SMT201800163T1 (en) 2012-09-11 2018-05-02 Coherus Biosciences Inc Correctly folded etanercept in high purity and excellent yield
KR102073748B1 (en) 2013-01-31 2020-02-05 한미약품 주식회사 Recombinant yeast transformant and process for preparing immunoglobulin Fc fragment employing the same
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
AR096891A1 (en) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
KR102530900B1 (en) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. Methods of treating nail and scalp psoriasis
CA2960642A1 (en) 2014-09-10 2016-03-17 Georgetown University Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
JP7175608B2 (en) 2014-11-19 2022-11-21 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク Osteocalcin as a treatment for age-related frailty
EP3268042B1 (en) 2015-03-13 2024-11-27 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
CA3082365A1 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
KR20210152472A (en) 2019-03-11 2021-12-15 메모리얼 슬로안 케터링 캔서 센터 CD22 antibody and methods of using the same
TW202237135A (en) 2021-01-13 2022-10-01 紀念斯隆凱特琳癌症中心 Antibody-pyrrolobenzodiazepine derivative conjugate
KR20230146522A (en) 2021-01-13 2023-10-19 메모리얼 슬로안 케터링 캔서 센터 Anti-DLL3 antibody-drug conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269455A3 (en) * 1986-11-28 1989-09-06 Takeda Chemical Industries, Ltd. Highly purified fused protein comprising human ige fc fragment and production thereof
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
WO1991002743A1 (en) * 1989-08-23 1991-03-07 The General Hospital Corporation Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE59010933D1 (en) * 1989-09-12 2003-05-08 Hoffmann La Roche TFN-binding proteins
EP0574395B1 (en) * 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides

Also Published As

Publication number Publication date
PT98113A (en) 1992-05-29
DE59109269D1 (en) 2005-12-15
ATE169030T1 (en) 1998-08-15
LU90592I2 (en) 2000-07-31
GR3027567T3 (en) 1998-11-30
AU655421B2 (en) 1994-12-22
KR100249572B1 (en) 2000-03-15
EP0835939A2 (en) 1998-04-15
CY2000009I1 (en) 2016-10-05
KR920000789A (en) 1992-01-29
UY25897A1 (en) 2001-01-31
EP0464533A1 (en) 1992-01-08
ES2120949T3 (en) 1998-11-16
DE59109032D1 (en) 1998-09-03
DE10075010I1 (en) 2003-06-12
JPH05247094A (en) 1993-09-24
EP0464533B1 (en) 1998-07-29
DK0835939T3 (en) 2006-03-13
ATE309376T1 (en) 2005-11-15
NL300009I1 (en) 2000-08-01
EP0835939B1 (en) 2005-11-09
JP3768427B2 (en) 2006-04-19
AU7935791A (en) 1992-01-02
HK1012015A1 (en) 1999-07-23
NL300009I2 (en) 2000-12-01
KR100280070B1 (en) 2001-01-15
DE10075010I2 (en) 2004-01-29
JP2002201200A (en) 2002-07-16
KR100280069B1 (en) 2001-01-15
PT98113B (en) 1998-12-31
ES2120949T4 (en) 2011-12-29
DK0464533T3 (en) 1999-04-26
EP1586635A1 (en) 2005-10-19
ES2251009T3 (en) 2006-04-16
EP0835939A3 (en) 1998-04-22
CA2045869A1 (en) 1991-12-29
EP0835939B8 (en) 2006-01-11
HK1010216A1 (en) 1999-06-17
IE912256A1 (en) 1992-01-01
CA2045869C (en) 2009-01-27

Similar Documents

Publication Publication Date Title
CY2151B1 (en) Fusionproteins with parts of immunoglobulins theirproduction and use
HK129394A (en) Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor
DE69228701D1 (en) Fragments of prion proteins.
AU7575487A (en) Method for the preparation of proteins with factor VIII activity by microbial host cells; expression, vectors, host cells, antibodies
EP0150735A3 (en) Method and composition for preparation of factor viiic
Sarfati et al. Purification and partial biochemical characterization of IgE-binding factors secreted by a human B lymphoblastoid cell line
DE3585953D1 (en) DNA FRAGMENTS, EXPRESSION VECTORS, PROTEINS, INNOVATORS AND METHOD FOR PRODUCING THE PROTEINS.
DE3581288D1 (en) ANTILEISHMANIA MONOCLONAL ANTI-BODIES, THESE ANTI-BODY ELIMINATING HYBRIDOMAS, LEISHMANIA-ANTIGENS RECOGNIZED BY THESE ANTI-BODIES, METHODS FOR THE PRODUCTION AND USE OF THESE MONOCLONAL ANTI-ANODIERS AND ANTIBODIES.
WO1998023750A3 (en) Mammalian chemokines
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
WO1998012334A3 (en) Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
WO1999003993A3 (en) Suppressors of cytokine signaling; related reagents
ATE294237T1 (en) MAMMAL THYMOKEGENS
Rapoport Intracellular compartmentation and secretion of carp proinsulin synthesized in Xenopus oocytes
Rao et al. Affinity purification of human brain tissue factor utilizing factor VII bound to immobilized anti-factor VII
DE3579808D1 (en) ANTI-UROKINASE MONOCLONAL ANTIBODY, ITS PRODUCTION AND USE.
FI885025A0 (en) KOAGULATIONSHAEMMANDE PROTEIN PP4-X, DESS FRAMSTAELLNING OCH ANVAENDNING.
CA2218755A1 (en) Monoclonal antibody to human beta 2 integrin alpha subunit
EP0305960A3 (en) A transformant cell line capable of producing a human monoclonal antibody, hybridoma, their production and use
Alcaraz et al. Tryptic and plasmic cleavage of a rat myeloma IgD
IE871932L (en) Method for the preparation of proteins with factor viii¹activity by microbial host cells, expression vectors, host¹cells, antibodies
MX9700255A (en) METHOD FOR IDENTIFYING NUCLEIC ACIDS ENCODING c-fos PROMOTER ACTIVATING PROTEINS.